Document ID: chunk:federal_register_of_legislation:F2022C00577:front:0:p4
Version: federal_register_of_legislation:F2022C00577
Segment Type: other
Provision Reference: 
Character Range: 8770–11747

onset of hypogonadism;
            Note: chronic kidney disease is defined in the Schedule 1 - Dictionary.
(20)      having anorexia nervosa at the time of the clinical onset of hypogonadism;
(21)      taking a course of systemic cytotoxic drugs for treatment of a malignant neoplasm before the clinical onset of hypogonadism;
(22)      taking gonadotrophin releasing hormone agonists or antagonists as androgen or estrogen deprivation therapy for at least 1 year within the 2 years before the clinical onset of hypogonadism;
(23)      having active epilepsy before the clinical onset of hypogonadism;
            Note: active epilepsy is defined in the Schedule 1 - Dictionary.
(24)      taking a drug from the Specified List 1 of drugs before the clinical onset of hypogonadism;
            Note: Specified List 1 of drugs is defined in the Schedule 1 - Dictionary.
(25)      taking an immune checkpoint inhibitor within the 1 year before the clinical onset of hypogonadism;
            Note: immune checkpoint inhibitor is defined in the Schedule 1 - Dictionary.
(26)      taking a drug from the Specified List 2 of drugs, which cannot be ceased or substituted, at the time of the clinical onset of hypogonadism;
            Note: Specified List 2 of drugs is defined in the Schedule 1 - Dictionary.
(27)      taking a drug which cannot be ceased or substituted and which is associated in the individual with the clinical onset of hypogonadism during drug therapy and either:
(a)          the improvement of hypogonadism within 2 months of discontinuing or tapering drug therapy; or
(b)           the redevelopment of hypogonadism on rechallenge with the same drug; and
where taking the drug continued for at least the 30 days before the clinical onset of hypogonadism;
(28)      inhaling fumes from a metal from the specified list of metals or a compound containing a metal from the specified list of metals:
(a)          for a cumulative period of at least 2,000 hours before the clinical onset of hypogonadism; and
(b)          if that exposure has ceased before the clinical onset of hypogonadism, then that onset occurred within 2 years of cessation;
            Note: fumes and specified list of metals are defined in the Schedule 1 - Dictionary.
(29)      inhaling, ingesting or having cutaneous contact with a chemical agent from the specified list of chemical agents:
(a)          for a cumulative period of at least 2,000 hours before the clinical onset of hypogonadism; and
(b)          if that exposure has ceased before the clinical onset of hypogonadism, then that onset occurred within 2 years of cessation;
            Note: specified list of chemical agents is defined in the Schedule 1 - Dictionary.
(30)      for females only, inhaling, ingesting or having cutaneous contact with a chemical agent contaminated by 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD):
(a)          for a cumulative period of at least 1,000 hours, within a consecutive period of 10